T1	p 6 46	Recurrent epithelial ovarian carcinoma :
T2	p 233 275	patients with epithelial ovarian carcinoma
T3	p 318 360	first-line , platinum-based chemotherapy .
T4	p 382 390	Patients
T5	p 396 434	measurable and assessable disease were
T6	p 587 625	Patients were stratified prospectively
T7	p 700 701	.
T8	p 718 738	of 474 patients were
T9	p 777 778	.
T10	p 798 813	intent-to-treat
T11	p 1120 1147	platinum-sensitive patients
T12	p 1401 1407	median
T13	i 79 129	pegylated liposomal doxorubicin versus topotecan .
T14	i 176 229	pegylated liposomal doxorubicin ( PLD ) and topotecan
T15	i 346 360	chemotherapy .
T16	i 457 475	either PLD 50 mg/m
T17	i 478 479	2
T18	i 487 502	1-hour infusion
T19	i 509 538	4 weeks or topotecan 1.5 mg/m
T20	i 630 638	platinum
T21	i 749 778	239 PLD and 235 topotecan ) .
T22	i 950 967	PLD and topotecan
T23	i 1068 1071	PLD
T24	i 1076 1080	56.7
T25	i 1091 1102	topotecan .
T26	i 1202 1205	PLD
T27	i 1271 1278	for PLD
T28	i 1286 1290	23.3
T29	i 1301 1312	topotecan .
T30	i 1336 1339	PLD
T31	i 1370 1379	topotecan
T32	i 1618 1627	topotecan
T33	i 1695 1708	growth factor
T34	i 1846 1849	PLD
T35	o 153 165	efficacy and
T36	o 411 421	assessable
T37	o 831 870	overall progression-free survival rates
T38	o 923 945	overall response rates
T39	o 1020 1049	Median overall survival times
T40	o 1210 1237	progression-free survival (
T41	o 1317 1339	overall survival , PLD
T42	o 1370 1379	topotecan
T43	o 1506 1526	significant survival
T44	o 1569 1596	Severe hematologic toxicity
T45	o 1695 1737	growth factor or blood product utilization
T46	o 1766 1774	efficacy
T47	o 1777 1803	favorable safety profile ,